{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:13:26Z","timestamp":1788408806379,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00466-4","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:08Z","timestamp":1787237588000},"page":"529-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-5008","authenticated-orcid":false,"given":"Roman","family":"Pfister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"466_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"466_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025;46:999\u20131013.","journal-title":"Eur Heart J"},{"key":"466_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jacc.2025.09.013","volume":"87","author":"A Masri","year":"2026","unstructured":"Masri A, Judge DP, Ruberg FL, Gillmore JD, Grodin JL, Obici L, et al. Effect of acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM: exploratory analysis from ATTRibute-CM. J Am Coll Cardiol. 2026;87:490\u2013501.","journal-title":"J Am Coll Cardiol"},{"key":"466_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16\u201326.","journal-title":"Circulation"},{"key":"466_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134785","volume":"14","author":"C Tschope","year":"2025","unstructured":"Tschope C, Elsanhoury A, Kristen AV. Transthyretin amyloid cardiomyopathy-2025 update: current diagnostic approaches and emerging therapeutic options. J Clin Med. 2025;14:4785.","journal-title":"J Clin Med"},{"key":"466_CR6","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","volume":"43","author":"S Law","year":"2022","unstructured":"Law S, Bezard M, Petrie A, Chacko L, Cohen OC, Ravichandran S, et al. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J. 2022;43:2622\u201332.","journal-title":"Eur Heart J"},{"key":"466_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.042530","volume":"14","author":"BW Sperry","year":"2025","unstructured":"Sperry BW, Masri A, Soman P, Ejaz AU, Bhattacharya P, Medoff B, et al. Changing patterns of diagnosis and survival in transthyretin cardiac amyloidosis: a multicenter cohort study. J Am Heart Assoc. 2025;14:e042530.","journal-title":"J Am Heart Assoc"},{"key":"466_CR8","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7\u201322.","journal-title":"Circulation"},{"key":"466_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","volume":"82","author":"A Porcari","year":"2020","unstructured":"Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J Intern Med. 2020;82:7\u201315.","journal-title":"Eur J Intern Med"},{"key":"466_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132\u201342.","journal-title":"N Engl J Med"},{"key":"466_CR11","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","volume":"85","author":"MS Maurer","year":"2025","unstructured":"Maurer MS, Judge DP, Gillmore JD, Garcia-Pavia P, Masri A, Cappelli F, et al. Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy. J Am Coll Cardiol. 2025;85:1911\u201323.","journal-title":"J Am Coll Cardiol"},{"key":"466_CR12","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","volume":"61","author":"M Miller","year":"2018","unstructured":"Miller M, Pal A, Albusairi W, Joo H, Pappas B, Haque Tuhin MT, et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem. 2018;61:7862\u201376.","journal-title":"J Med Chem"},{"key":"466_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/phar.4639","volume":"45","author":"EL Hellenbart","year":"2025","unstructured":"Hellenbart EL, Ipema HJ, Rodriguez-Ziccardi MC, Krishna H, DiDomenico RJ. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications. Pharmacotherapy. 2025;45:124\u201344.","journal-title":"Pharmacotherapy"},{"key":"466_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","volume":"47","author":"M Fontana","year":"2025","unstructured":"Fontana M, Aimo A, Emdin M, Porcari A, Solomon SD, Hawkins PN, et al. Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Eur Heart J. 2025;47:54\u201363.","journal-title":"Eur Heart J"},{"key":"466_CR15","unstructured":"U.S. Food & Drug Administration. ATTRUBY (acoramidis) prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf. Accessed 29 July 2026."},{"key":"466_CR16","unstructured":"European Medicines Agency. Beyonttra (acoramidis) summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyonttra-epar-product-information_en.pdf. Accessed 29 July 2026."},{"key":"466_CR17","unstructured":"Pharmaceuticals and Medical Devices Agency. Beyonttra (acoramidis) Japanese prescribing information. 2025. https:\/\/www.pmda.go.jp\/files\/000278404.pdf. Accessed 29 July 2026."},{"key":"466_CR18","unstructured":"Medicines & Healthcare Products Regulatory Agency. BEYONTTRA: Summary of product characteristics. 2025. https:\/\/products.mhra.gov.uk\/search\/?search=beyonttra&page=1. Accessed 29 July 2026."},{"key":"466_CR19","unstructured":"Swissmedic. BEYONTTRA\u00ae, film-coated tablets (acoramidisum). Swissmedic. 2025. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/beyonttra-filmtabletten-acoramidisum.html. Accessed 29 July 2026."},{"key":"466_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15093355","volume":"15","author":"J Costantino","year":"2026","unstructured":"Costantino J, Ballatore F, Marchionni G, Alfarano M, Stavagna S, Costantino S, et al. Serum transthyretin as a prognostic and therapeutic biomarker in transthyretin amyloid cardiomyopathy patients treated with tafamidis. J Clin Med. 2026;15:3355.","journal-title":"J Clin Med"},{"key":"466_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102208","volume":"4","author":"D Terentes-Printzios","year":"2025","unstructured":"Terentes-Printzios D, Koilakou ME, Alexiou P, Antonopoulos A, Kasiakogias A, Katsimichas T, et al. Serum transthyretin as prognostic biomarker for cardiovascular events and mortality: a systematic review and meta-analysis. JACC Adv. 2025;4:102208.","journal-title":"JACC Adv"},{"key":"466_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2088","volume":"24","author":"MS Maurer","year":"2024","unstructured":"Maurer MS, Cappelli F, Fontana M, Garcia-Pavia P, Grogan M, Hanna M, et al. Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension. Eur Heart J. 2024;24:ehae666.2088.","journal-title":"Eur Heart J"},{"key":"466_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.12.082","author":"B Ansari","year":"2026","unstructured":"Ansari B, Barrera Nelson I, Bampatsias D, Teruya S, Mirabal-Santos A, Helmke S, et al. Increase in serum transthyretin after tafamidis is associated with improved survival in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2025.12.082","journal-title":"J Am Coll Cardiol"},{"key":"466_CR24","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","volume":"83","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. J Am Coll Cardiol. 2024;83:1276\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"466_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","volume":"10","author":"A Ioannou","year":"2025","unstructured":"Ioannou A, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, et al. Kidney outcomes in transthyretin amyloid cardiomyopathy. JAMA Cardiol. 2025;10:50\u20138.","journal-title":"JAMA Cardiol"},{"key":"466_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","volume":"84","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Fumagalli C, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, et al. Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2024;84:43\u201358.","journal-title":"J Am Coll Cardiol"},{"key":"466_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.17925\/HI.2025.19.1.5","volume":"19","author":"A Ioannou","year":"2025","unstructured":"Ioannou A. Monitoring disease progression in transthyretin amyloid cardiomyopathy. Heart Int. 2025;19:20\u20135.","journal-title":"Heart Int"},{"key":"466_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ejhf.2113","volume":"23","author":"V Castiglione","year":"2021","unstructured":"Castiglione V, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail. 2021;23:217\u201330.","journal-title":"Eur J Heart Fail"},{"key":"466_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","volume":"11","author":"JLS Hanson","year":"2018","unstructured":"Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11:e004000.","journal-title":"Circ Heart Fail"},{"key":"466_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.01.009","author":"V Castiglione","year":"2026","unstructured":"Castiglione V, Aimo A, Franzini M, Castiglione A, Palmieri G, Chubuchna O, et al. Serum transthyretin before and after starting tafamidis as outcome predictors in ATTR cardiomyopathy. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2026.01.009.","journal-title":"J Am Coll Cardiol"},{"key":"466_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","volume":"151","author":"DP Judge","year":"2025","unstructured":"Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation. 2025;151:601\u201311.","journal-title":"Circulation"},{"key":"466_CR32","doi-asserted-by":"publisher","first-page":"37893","DOI":"10.1038\/s41598-025-21779-9","volume":"15","author":"M Poledniczek","year":"2025","unstructured":"Poledniczek M, Schmid LM, Kronberger C, Ermolaev N, Rettl R, Binder C, et al. Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients. Sci Rep. 2025;15:37893.","journal-title":"Sci Rep"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00466-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:23:40Z","timestamp":1788405820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00466-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00466-4","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roman Pfister received speaker and consultancy fees by Alnylam, AstraZeneca, Bayer, and Pfizer; and research grants by Alnylam, Bayer, and Pfizer. Lars Michel received personal fees from Alnylam, AstraZeneca, Bayer, Bristol Myers Squibb, IFFM e.V., Pfizer, and from Bund der Niedergelassenen Kardiologen (BNK) outside of the submitted work; research funding from IFORES Clinician Scientist Scholarship from the Faculty of Medicine, University of Duisburg-Essen and initiative research grant, University Medicine Foundation, University Medicine Essen, Germany; research funding from Bayer for an investigator\/institution-sponsored collaborative study, outside the submitted work. Marcel Schulze, Kai Vogtl\u00e4nder, and Martin Merz are employees and stockholders of Bayer AG. Antonio Ciaccia is an employee and stockholder of Bayer Inc. Christian Hengstenberg reports consulting activities and honoraria from Abbott, Boston Scientific, Edwards LifeSciences, Medtronic, and Meril; and institutional research support from Abbott, Boston Scientific, Cordis, Edwards LifeSciences, Medtronic, Meril, and Johnson & Johnson.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is being conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and all applicable laws and regulations. The protocol has been approved under the EU Clinical Trials Regulation, with Clinical Trial Application Part I (regulatory) and Part II (ethical) approvals granted in all participating countries (EU Clinical Trials Number: 2025-521831-35-00). The study was approved by the institutional review board or independent ethics committee at each site. Permission was obtained to use the Kansas City Cardiomyopathy Questionnaire overall summary score and EuroQol 5-dimension 5-level scores. All participants are required to provide signed, informed consent before enrollment into the study. Personal and study-related information will be collected and used in accordance with local data protection law, and is explained in detail in the informed consent and privacy statement available to participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}